PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights
Globe Newswire•10/11/2026•08:00 ET
0
Key Highlights
- ➤$50 million public offering closed, extending expected cash runway into Q1 2028
- ➤Rezatapopt ovarian-cancer cohort posted 46% ORR in 76-patient interim analysis
- ➤NDA submission for platinum-resistant/refractory ovarian cancer planned for Q1 2027
- ➤$108.5 million cash, equivalents, and marketable securities held at September 30
- ➤Net loss widened to $34.4 million from $21.1 million year over year
Expert Statements
David Mack, President and Chief Executive Officer of PMV Pharma
“We achieved significant milestones during the third quarter across the organization.”
David Mack, President and Chief Executive Officer of PMV Pharma
“The updated monotherapy interim data demonstrate the potential for rezatapopt to address a significant unmet medical need.”
David Mack, President and Chief Executive Officer of PMV Pharma
“The completed $50 million public offering also positions us well to submit an NDA in the first quarter of 2027 seeking accelerated approval for treatment of platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutation.”
* Pivotal Phase 2 rezatapopt PYNNACLE data to be featured in late-breaking oral presentation at ENA 2026
* Announced closing of oversubscribed $50 million public offering of securities
Get started
Create a free account to read the full story.